A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma

Michael G Ozawa^{1,6}, Aparna Bhaduri^{2,6}, Karen M Chisholm³, Steven A Baker¹, Lisa Ma¹, James L Zehnder^{1,4}, Sandra Luna-Fineman⁵, Michael P Link⁵, Jason D Merker¹, Daniel A Arber¹ and Robert S Ohgami¹

¹Department of Pathology, Stanford University, Stanford, CA, USA; ²Program in Epithelial Biology, Stanford University, Stanford, CA, USA; ³Department of Laboratories, Seattle Children's Hospital, Seattle, WA, USA; ⁴Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA and ⁵Department of Pediatrics, Stanford University, Stanford, CA, USA

Pediatric-type follicular lymphoma and pediatric marginal zone lymphoma are two of the rarest B-cell lymphomas. These lymphomas occur predominantly in the pediatric population and show features distinct from their more common counterparts in adults: adult-type follicular lymphoma and adult-type nodal marginal zone lymphoma. Here we report a detailed whole-exome deep sequencing analysis of a cohort of pediatric-type follicular lymphomas and pediatric marginal zone lymphomas. This analysis revealed a recurrent somatic variant encoding p.Lys66Arg in the transcription factor interferon regulatory factor 8 (IRF8) in 3 of 6 cases (50%) of pediatric-type follicular lymphoma. This specific point mutation was not detected in pediatric marginal zone lymphoma or in adult-type follicular lymphoma. Additional somatic point mutations in pediatric-type follicular lymphoma were observed in genes involved in transcription, intracellular signaling, and cell proliferation. In pediatric marginal zone lymphoma, no recurrent mutation was identified; however, somatic point mutations were observed in genes involved in cellular adhesion, cytokine regulatory elements, and cellular proliferation. A somatic variant in *AMOTL1*, a recurrently mutated gene in splenic marginal zone lymphoma, was also identified in a case of pediatric marginal zone lymphoma. The overall non-synonymous mutational burden was low in both pediatric-type follicular lymphoma and pediatric marginal zone lymphoma (4.6 mutations per exome). Altogether, these findings support a distinctive genetic basis for pediatric-type follicular lymphoma and pediatric marginal zone lymphoma when compared with adult subtypes and to one another. Moreover, identification of a recurrent point mutation in *IRF8* provides insight into a potential driver mutation in the pathogenesis of pediatric-type follicular lymphoma with implications for novel diagnostic or therapeutic strategies.

Modern Pathology (2016) 29, 1212–1220; doi:10.1038/modpathol.2016.102; published online 24 June 2016

Non-Hodgkin lymphomas are estimated to be the fourth most common malignancy in children and fifth most common in the adolescent and young adult population. Although aggressive mature B-cell lymphomas, including Burkitt lymphoma and diffuse large B-cell lymphoma, comprise a significant proportion of pediatric lymphomas and show many features similar to cases occurring in adults, indolent B-cell lymphomas, including pediatric-type

follicular lymphoma and pediatric nodal marginal zone lymphoma, are rare diseases with several distinctive characteristics in presentation and clinical behavior when compared with their adult counterparts.^{1–3} Pediatric-type follicular lymphoma is a distinct variant from the adult-type, typically seen between the ages of 3 and 18 years, though cases occurring in young adults have also been described.^{4,5} Pediatric-type follicular lymphoma shows a male predominance (approximately 4:1) and most often involves lymph nodes of the cervical regions, though extranodal occurrences in the testis, epididymis, and gastrointestinal tract have been reported.^{4,5} The majority of patients with pediatric-type follicular lymphoma, present with localized stage I disease and follow an indolent clinical course. The morphologic features are similar to those of the

Correspondence: MG Ozawa, MD, PhD or Professor RS Ohgami, MD, PhD, Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Room L235, Stanford 94305, CA, USA. E-mail: mgozawa@stanford.edu or rohgami@stanford.edu

⁶These authors contributed equally to this work.

Received 23 March 2016; revised 26 April 2016; accepted 1 May 2016; published online 24 June 2016

adult-type follicular lymphoma, with most cases showing increased atypical follicles comprised of cleaved small and larger centroblastic lymphocytes. Despite frequently showing more aggressive cytologic features (often grade 2 or grade 3 in morphology), patients with pediatric-type follicular lymphoma show excellent response rates to local surgical resection or minimal chemotherapy and have very low recurrence rates.⁴ Pediatric-type follicular lymphoma lacks the characteristic *IGH-BCL2*; t(14;18) (q32;q21) translocation found in ~80% of adult-type follicular lymphoma with absence of BCL2 protein expression. Recently, Martín-Guerrero *et al.* described recurrent loss of heterozygosity in 1p36 and association with *TNFRSF14* mutations in a small subset of pediatric-type follicular lymphoma patients.⁶

Comparably, arising from post-germinal center memory B-cells, pediatric nodal marginal zone lymphoma shares similar architectural and immunophenotypic features with the adult-type; however, distinct and characteristically, pediatric nodal marginal zone lymphoma demonstrates a male preponderance (approximately 20:1) and is largely localized to the head and neck regions.^{7,8} This lymphoma presents as stage 1 localized disease and carries an excellent prognosis and overall low rate of recurrence.⁹ Genetic aberrations in pediatric nodal marginal zone lymphoma have been described, with the most frequent alteration seen being trisomy 18 (17%), which is also a frequent cytogenetic abnormality found in adult-type nodal marginal zone lymphoma.^{10,11} Similar to pediatric-type follicular lymphoma, definitive diagnosis of pediatric nodal marginal zone lymphoma and separation from similar morphologic entities remains challenging.

Given the propensity for some overlapping features between pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma and the paucity of literature describing the genetic landscape of these distinct entities, we performed whole-exome deep sequencing (>140-fold coverage) on 10 cases of pediatric nodal marginal zone lymphoma and pediatric-type follicular lymphoma, as well as Sanger sequencing on two additional cases, to characterize the mutational signature of these rare tumors and search for additional driver mutations and involved biological pathways. Our analysis identified a novel recurrent somatic point mutation in pediatric-type follicular lymphoma in the transcription factor interferon regulator factor 8/interferon consensus-binding protein (*IRF8/ICSBP*), c.197A>G encoding p.Lys66Arg. Additional somatic variants were observed in pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma including mutations in genes involved in transcription, intracellular signaling and cellular organization though there was an overall low rate of non-synonymous mutations (4.6 mutations per case).

Materials and methods

Case Selection

Case records from the Department of Pathology, Stanford University Medical Center and Seattle Children's Hospital were reviewed from 1996 to 2015 for cases with a diagnosis of marginal zone lymphoma or follicular lymphoma in patients <30 years of age. All hematoxylin and eosin-stained slides, as well as all available supplementary material, were reviewed confirming the previously rendered diagnoses according to WHO criteria.⁸ A total of 12 cases were identified, 6 cases of pediatric-type follicular lymphoma and 6 cases of pediatric nodal marginal zone lymphoma. From this cohort, the clinical and morphologic features of one pediatric-type follicular lymphoma case with paired tumor-normal (uninvolved lymph node) set were recently reported.¹² An additional 22 cases of adult-type follicular lymphoma were selected as additional controls: 14 cases of adult-type follicular lymphoma grade 1–2; 6 cases of adult-type follicular lymphoma grade 3A; and 2 cases of adult-type follicular lymphoma grade 3B. This study was approved by Stanford's institutional review board.

Exome Library Preparation and Sequencing

Library preparation and exome sequencing were performed as previously described.^{13,14} In brief, DNA was extracted from formalin-fixed paraffin embedded tissue using Qiagen DNeasy kits according to the manufacturer's protocols. The Agilent SureSelect Exon V5 target enrichment system was used to enrich for a 51-Mb exome following Illumina HiSeq 2500 V3 platform sequencing using 100-bp paired-end reads, with high output mode coverage at 200× with 2×100 PE read length.

Alignment, Single-Nucleotide Variant, Copy-Number Variant and Indel Analysis

DNA sequence alignment was performed using BWA-MEM. Mutation analysis was performed with three mutation callers, Mutect (version 1.17), Sure-Call SNPPET (version 3.0, Agilent Technologies), and VarScan2.^{15,16} For all samples, callers were run with default settings in individual sample analysis modes. In order to call a mutation, 20× coverage of the base analyzed (as defined by the mutation caller itself) was required, as well as coverage in both the forward and reverse directions. Unequal representation of read counts (>80%/20% split) was additionally discounted. For the sample with a paired control, acquired mutations were considered when the allele frequency of the variant in the disease sample at least doubled the allele frequency of the variant in the control sample. For samples without a matched control, a minimum allele frequency of 0.1

was required in addition to the coverage restriction for initial analysis. Single-nucleotide polymorphisms identified in dbSNP, Exome Aggregation Consortium and Exome Variant Server were additionally curated and removed from further analysis. DNA from a paired normal lymph node sample, and three additional lymph nodes in unrelated patients without involvement by lymphoma were also sequenced: variants identified in case samples were compared with these controls to curate recurrent sequencing errors (ie, homopolymer errors, recurrent errors in GC-rich regions). Gene annotations were performed with SeattleSeq138 and Surecall (version 3.0; Agilent Technologies). Indel analysis was performed with GATK, Surecall, and VarScan2. GATK was run according to the Best Practices guidelines, with SureCall and VarScan2 run with default parameters. The above variant filtration was similarly applied to indel analysis. Copy-number variation analysis was performed with CNVSeq, run with default parameters, and analysis performed on the 'hits' file.

Sanger Sequencing of *IRF8*

Sanger sequencing was performed to detect the candidate *IRF8* variant with primers designed using PrimerQuest; primers are listed in Supplementary Table S1. Amplified DNA was sequenced and visualized using 4Peaks.¹⁷

Multi-Species Alignment and Single-Nucleotide Variant Effect Prediction

Data for the vertebrate MULTIZ alignments were retrieved from the UCSC Genome Browser, assembly ID: hg38. The translated regions comprising *IRF8* exon 1 and exon 2 were extracted and analyzed for conservation of K66. Three-dimensional protein structure homology modelling was performed using SWISS-MODEL as described.¹⁸ PolyPhen-2 and SIFT prediction algorithms were employed as previously described.^{19,20}

Results

Whole-Exome Sequencing and Data Analysis of Pediatric-Type Follicular Lymphoma and Pediatric Nodal Marginal Zone Lymphoma

To identify potential driver mutations, as well as characterize the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma, we performed whole-exome deep sequencing (>140-fold coverage) on six cases of pediatric-type follicular lymphoma, with one paired tumor-normal set, and four cases of pediatric nodal marginal zone lymphoma. All pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma cases were identified in patients aged 18 years or less (range: 12–18 years). The cases

were reviewed, and the morphologic and immunophenotypic features confirmed the respective diagnoses. The patient demographics and clinical features are detailed in Table 1.

Using our analytic pipeline consisting of three different variant calling algorithms, Mutect, SNPPEt, and VarScan, the observed somatic non-synonymous mutational burden per case was low with a mean of 4.6 mutations per case (range 2–13). To minimize false negatives, we employed more lenient filter parameters including a minimum of 10% allele frequency and a 10 read/ single-nucleotide variant coverage requirement. A total of 46 non-synonymous somatic mutations affecting 44 different genes were identified, including both missense mutations and nonsense mutations.³ In pediatric-type follicular lymphoma, we identified 32 single-nucleotide variants in genes involved in transcription, intracellular signaling, and cell proliferation (Table 2). Fewer mutations were detected in pediatric nodal marginal zone lymphoma, with 14 single-nucleotide variants observed in genes involved in cellular adhesion, cytokine regulatory elements, and cellular proliferation (Table 3).

In pediatric-type follicular lymphoma, we identified a recurrent somatic point mutation c.197A>G encoding p.Lys66Arg in the transcription factor interferon regulator factor 8/interferon consensus-binding protein (*IRF8*/ICSBP). This unique single-nucleotide variant was identified in three of six pediatric-type follicular lymphoma samples (Table 2). It was absent in the corresponding normal tissue sample from case 1. Sanger sequencing confirmed the single-nucleotide variant in all three cases. We further performed Sanger sequencing to detect the *IRF8* variant on the remainder of the pediatric-type follicular lymphoma cases, all pediatric nodal marginal zone lymphoma cases and 22 cases of adult-type follicular lymphoma; these cases were negative for the c.197A>G in *IRF8* (data not shown). No recurrent somatic mutations were observed in pediatric nodal marginal zone lymphoma.

IRF8 is a member of the IRF family of transcription factors, predominantly expressed in the cells of the immune system, which is a member of complex regulatory networks contributing to hematopoietic differentiation, cell cycle regulation, and apoptosis. The *IRF8* protein contains an N-terminal DNA-binding domain and a C-terminal IRF association domain. The p.Lys66Arg alteration is a conservative, charge-neutral residue substitution within the DNA-binding domain of *IRF8* (Figure 1a and b): specifically loop 2, which is C-terminal to alpha helix-2 (Figure 1b). Although falling within a long loop region, this position based on extrapolation from the highly homologous family member *IRF4* and the crystal structure of PU.1/*IRF4*/DNA complex, is predicted to affect DNA–protein interaction via the bulkier side group substitution.²² Furthermore, assessment of amino-acid sequence conservation in *IRF8* at position 66 revealed 100% sequence identity

Table 1 Patient demographics

Case	Diagnosis	Sex	Age, years	Site of involvement	Treatment	BCL2 protein expression	Ancillary studies
1 ^a	Pediatric-type follicular lymphoma	M	12	Parotid, left	Resection	Negative	BCL2 rearrangement negative (FISH); IgH clone positive
2	Pediatric-type follicular lymphoma	F	13	Lymph node, cervical	Excision	Negative	t(14;18) negative (PCR); Ig clone positive
3	Pediatric-type follicular lymphoma	M	15	Lymph node, cervical	Excision	Negative	t(14;18) negative (PCR); Ig clone positive
4	Pediatric-type follicular lymphoma	M	18	Tonsil	Excision	Weak positive, large B cells	N/A
5	Pediatric nodal marginal zone lymphoma	F	17	Lymph node left inguinal	Excision	N/A	N/A
6	Pediatric-type follicular lymphoma	M	12	Parotid, left	Resection	Periphery of follicle positive	t(14;18) negative
7	Pediatric nodal marginal zone lymphoma	M	16	Lymph node, cervical	Excision	Negative	N/A
8	Pediatric nodal marginal zone lymphoma	M	16	Lymph node, right posterior cervical	Excision	Negative	Ig clone positive
9	Pediatric nodal marginal zone lymphoma	M	14	Lymph node, right posterior auricular	Excision	Weakly/possibly positive	Ig clone positive
10	Pediatric-type follicular lymphoma	M	12	Lymph node, right cervical	Excision	Negative	BCL2 rearrangement negative (FISH); Ig clone positive
11	Pediatric nodal marginal zone lymphoma	M	15	Lymph node, cervical	Excision	Positive	Ig clone negative
12	Pediatric nodal marginal zone lymphoma	M	14	Lymph node, post auricular	Excision	Equivocal	IgH clone positive

Abbreviations: F, female; FISH, fluorescent *in situ* hybridization; M, male; pN/ZML, pediatric nodal marginal zone lymphoma.^aCase with paired uninvolved lymph node, cervical level II pediatric-type follicular lymphoma, and pediatric follicular lymphoma.

compared with 97 vertebrate species with aligned genomes (Figure 1c and Supplementary Table S2). In addition, PolyPhen2 and sorting intolerant from tolerant (SIFT) algorithms predict a deleterious effect of the p.Lys66Arg alteration.

Copy-Number Variants and Fusion Detection

Copy-number and/or structural variations are frequently associated with hematolymphoid neoplasms. We evaluated the whole-exome paired-end data set for pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma assessing for copy-number alterations and genomic fusion and break points. We employed CNV-seq to identify DNA copy-number variations using a threshold of twofold increase or decrease compared with control.²³ As not all of the samples had paired normal tissue, all samples were compared with the paired histologically confirmed uninvolved lymph node (normal tissue) from case 1. With this analysis, no recurrent chromosomal site to suggest large genomic copy-number alterations was identified in pediatric-type follicular lymphoma or pediatric nodal marginal zone lymphoma.

For detection of genomic rearrangements, we used the previously described software tool Fusion and Chromosomal Translocation Enumeration and Recovery Algorithm.²⁴ This highly sensitive and specific method uses paired-end DNA sequencing data to rapidly identify translocations, inversions, and large deletions. Three structural variations were identified in three separate cases of pediatric-type follicular lymphoma (Supplementary Table S3): two variants were deletions spanning the immunoglobulin kappa joining region and the variable region (case 4 and 6), and the third was a deletion present in the immunoglobulin heavy chain variable region (case 1). These deletions likely represented normal immunoglobulin heavy chain and immunoglobulin kappa gene rearrangements (Table 1). No gene fusions were identified in pediatric-type follicular lymphoma. No translocations, inversions, or deletions were identified in pediatric nodal marginal zone lymphoma.

Comparison with Variants in Adult-Type Follicular Lymphoma and Adult-Type Nodal Marginal Zone Lymphoma

Given the similar morphologic and phenotypic features of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma with the corresponding adult types, we sought to compare the identified single-nucleotide variants with published reports for alterations in adult-type follicular lymphoma and adult-type nodal marginal zone lymphoma. No mutations were observed in pediatric-type follicular lymphoma in chromatin regulatory elements (*CREBBP*, *EZH2*, *KMT2D*

Table 2 Somatic mutations identified by whole-exome sequencing in pediatric-type follicular lymphoma

Gene	Chr	Position	Variant allele frequency (%)	Nucleotide change	AA change	Function class	Case
<i>IRF8</i>	16	85 942 618	20	A/G	Lys/Arg	MISSENSE	1
<i>IRF8</i>	16	85 942 618	11	A/G	Lys/Arg	MISSENSE	2
<i>IRF8</i>	16	85 942 618	14	A/G	Lys/Arg	MISSENSE	6
<i>PAX5</i>	9	37 002 701	11	G/C	Gly/Ala	MISSENSE	1
<i>INPP5B</i>	1	38 339 723	29	A/C	Glu/Asp	MISSENSE	2
<i>RPE</i>	2	210 880 950	23	A/G	Glu/Gly	MISSENSE	2
<i>MON1A</i>	3	49 946 502	27	G/A	Arg/His	MISSENSE	2
<i>PTPN13</i>	4	87 706 461	29	G/T	Asp/Tyr	MISSENSE	2
<i>ETV1</i>	7	13 940 391	23	A/G	Tyr/Cys	MISSENSE	2
<i>ATP6V1H</i>	8	112 148 158	26	T/A	Phe/Leu	MISSENSE	2
<i>ACAD10</i>	12	37 944 567	21	G/C	Val/Leu	MISSENSE	2
<i>IKZF3</i>	17	1 615 443	24	A/G	Arg/Gly	MISSENSE	2
<i>TCF3</i>	19	11 547 254	20	A/G	Asn/Asp	MISSENSE	2
<i>PRKCSH</i>	19	84 585 965	22	G/A	Gly/Ser	MISSENSE	2
<i>POF1B</i>	X	134 711 306	21	A/T	Ile/Phe	MISSENSE	2
<i>DDX26B</i>	X	85 942 618	21	G/A	Trp/stop	NONSENSE	2
<i>FOXF1</i>	16	51 274 901	38	G/A	Gly/Ser	MISSENSE	3
<i>GPR32</i>	19	41 337 433	30	T/A	Cys/stop	NONSENSE	3
<i>CNTN1</i>	12	41 821 754	37	A/C	Asn/His	MISSENSE	4
<i>RPAP1</i>	15	105 165 757	36	C/T	Arg/stop	NONSENSE	4
<i>LRP1</i>	12	57 585 219	15	C/A	Ser/Arg	MISSENSE	6
<i>MAP2K1</i>	15	66 727 441	19	T/G	Phe/Val	MISSENSE	6
<i>PDCD11</i>	10	32 929 982	35	G/A	Val/Ile	MISSENSE	6
<i>ARHGAP11A</i>	15	85 401 669	35	G/A	Gly/Asp	MISSENSE	6
<i>ALPK3</i>	15	65 955 762	35	G/A	Ala/Thr	MISSENSE	6
<i>BPTF</i>	17	85 942 618	26	C/G	Pro/Ala	MISSENSE	6
<i>GALNT6</i>	12	52 863 611	38	A/G	Gln/Arg	MISSENSE	10
<i>KRT6C</i>	12	36 046 590	40	G/T	Ala/Ser	MISSENSE	10
<i>NBEA</i>	13	70 924 697	38	A/G	Lys/Glu	MISSENSE	10
<i>ADAM21</i>	14	82 336 301	20	A/G	Ile/Val	MISSENSE	10
<i>MEX3B</i>	15	72 141 313	37	G/A	Gly/Arg	MISSENSE	10
<i>DHX38</i>	16	112 148 158	38	C/G	Ala/Gly	MISSENSE	10

Abbreviation: AA, amino acid.

Table 3 Somatic mutations identified by whole-exome sequencing in pediatric nodal marginal zone lymphoma

Gene	Chr	Position	Variant allele frequency (%)	Nucleotide change	AA change	Function Class	Case
<i>AMOTL1</i>	11	94 602 545	35	G/A	Ala/Thr	MISSENSE	5
<i>SCAF1</i>	19	50 156 770	39	C/T	Pro/Ser	MISSENSE	5
<i>SELPLG</i>	12	109 017 471	21	G/C	Ala/Phe	MISSENSE	7
<i>FAM5B</i>	1	177 225 175	39	T/A	Asn/Lys	MISSENSE	7
<i>KLHDC4</i>	16	87 799 459	40	G/A	Gly/Asp	MISSENSE	7
<i>RAX</i>	18	56 940 300	37	A/T	Ile/Phe	MISSENSE	7
<i>PEG3</i>	19	57 328 464	37	C/T	Ala/Val	MISSENSE	7
<i>CHPF</i>	2	220 404 500	38	C/G	Gln/Glu	MISSENSE	8
<i>ACTRT3</i>	3	169 486 133	34	C/G	Pro/Arg	MISSENSE	8
<i>NRCAM</i>	7	107 872 965	36	T/G	Phe/Val	MISSENSE	8
<i>CHMP1A</i>	16	89 717 990	36	C/T	Ala/Val	MISSENSE	8
<i>CISH</i>	3	50 645 112	36	G/C	Val/Leu	MISSENSE	9
<i>TTC17</i>	11	43 413 032	36	A/G	Asp/Gly	MISSENSE	9
<i>NLE1</i>	17	33 460 462	39	G/C	Ala/Pro	MISSENSE	9

Abbreviation: AA, amino acid.

(*MLL2*), members of the TNF family (*TNFRSF14*), *NF- κ B* signaling, or *mTORC1*;^{25–28} however, case 2, which also harbored an *IRF8* mutation, contained a mutation in the transcription factor *PAX5*, p. Gly183Ala. This mutation was not seen in the paired normal tissue; whereas this mutation in *PAX5* has not been reported previously in adult-type follicular

lymphoma, mutations in G183 have been identified in patients with B-lymphoblastic leukemia.²¹

Translocations involving *BCL2* were not observed by exome sequencing or by fluorescence *in situ* hybridization studies (Supplementary Table S4). However, in pediatric nodal marginal zone lymphoma, we observed a single case with a non-

Figure 1 Recurrent point mutation in the DNA-binding domain of IRF8. (a) Schematic diagram of the IRF8 protein with demarcation of the DNA-binding domain and IRF association domain. Stars indicate location and number of cases with K66R substitution. (b) Ribbon model of the DNA-binding domain with the side chain of R66 visualized. Inset, ribbon model with wild-type sequence. (c) Multi-species alignment of IRF8 spanning exon 1 and exon 2 (amino acids 1–87) with highlighted conserved lysine at position 66 across multiple species.

synonymous mutation in Angiogenin like-1 (*AMOTL1*) c.2671G>A (p.Ala891Thr); this specific point mutation has been identified previously in a patient with carcinoma of the large intestine (COSMIC ID: COSM1357979). *AMOTL1* is a coiled-coil, PDZ-binding and glutamine-rich domain containing protein that has recently been described as recurrently mutated in splenic marginal zone lymphoma.²⁹ *AMOTL1* mutations were not observed in pediatric-type follicular lymphoma cases. Moreover, no global copy-number alterations to support trisomies seen in adult-type nodal marginal zone lymphoma, such as trisomy 3 and 18 were seen; however, two of the cases (case 8 and 9) had detected B-cell clonal rearrangements. In keeping with the low incidence of translocations in adult-type nodal marginal zone lymphoma, none were observed in pediatric nodal marginal zone lymphoma. The reported 7q32 deletion and 8q23 gain seen in splenic marginal zone lymphoma were not identified. Mutations in additional genes known to be mutated in marginal zone lymphomas such as those in Kruppel-like factor 2 (*KLF2*), *MYD88*, *TP53*, *CDKN2A*, *NOTCH1*, *NOTCH2*, *BRAF*, *TRAF3*, *TNFAIP3*, *CARD11*, and others, which have been described in adult marginal zone lymphomas were not seen in pediatric nodal marginal zone lymphoma (Supplementary Table S4).^{27,30,31}

Discussion

Pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma are extremely rare

diseases, which share features with their corresponding adult types, but show distinct differences in clinical behavior. The basis for these distinct differences is not well understood. Here we performed whole-exome deep sequencing on cases of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma to better characterize the genetic landscape of these diseases and identify driver mutations. Both diseases showed overall low somatic mutation rates (on average 4.6 mutations per exome); mutations identified in pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma were seen in pathways important for transcription, intracellular signaling and cellular organization. Importantly, we identified a recurrent and specific somatic point mutation in *IRF8* present in three cases of pediatric-type follicular lymphoma and absent in the normal tissue from a paired sample. This variant encodes a p.Lys66Arg, which falls within the DNA-binding domain of the protein and is predicted to result in deleterious effects. In addition, *IRF8* p.Lys66Arg was not detected in pediatric nodal marginal zone lymphoma or cases of adult-type follicular lymphoma. To our knowledge, this is the first published report detailing the mutational landscape of these diseases and the first description of a potential driver mutation in pediatric-type follicular lymphoma.

In contrast to adult-type follicular lymphoma, which shows a characteristic *BCL2* chromosomal translocation, as well as additional common chromosomal and gene changes, the genetic underpinnings of pediatric-type follicular lymphoma

development have not been clearly defined.³² Martin-Guerrero *et al*, recently reported recurrent loss of heterozygosity at 1p36, a site commonly altered in adult-type follicular lymphoma, which was primarily associated with *TNFRSF14* mutations.⁶ *EZH2* mutations were also reported in the same cohort, lending some support to potential genetic mechanisms as the adult form.³³ *IRF8* was recently described as a recurrently mutated gene in a small percentage of cases of adult-type follicular lymphoma.³⁴ Notably, the variants were predominantly located in the C-terminal domain of *IRF8* with unclear functional consequences and a recurrent nucleotide change was not reported. Identification of the specific p.Lys66Arg substitution in a significant portion of our pediatric-type follicular lymphoma cohort is highly suggestive of a common and critical alteration, leading to the disease development. Moreover, although a similar gene is implicated between the adult and pediatric forms, the recurrent alteration in the DNA-binding domain suggests potentially a unique disease origin.

The interferon regulatory factor (IRF) superfamily of transcription factors consists of nine members with roles in transcriptional regulation of interferon (IFN)-inducible genes, as well as increasingly recognized roles in immune development and function. *IRF8/ICSBP* is induced by type II IFN and is expressed by hematopoietic cells, as well as other tissues. *IRF8* serves a key role in T-cell and dendritic cell development, as well as differentiation and function of macrophages, T-cells and B cells.^{34–38} In B-cells, *IRF8*, with the highly homologous protein *IRF4*, functions in pre-B cells to regulate light-chain rearrangement and is required for differentiation from pre-B-cells to immature B-cells.^{37,39} *IRF8* and *IRF4* induce expression of the transcription factors *ikaros* and *aiolos*, which serve as negative regulators of pre-B-cell receptor signaling and cell cycle progression through direct c-Myc inhibition.⁴⁰ Notably, deficiency of *IRF4* and *IRF8* induces a hyperproliferative phenotype in pre-B cells, though reconstitution of either *IRF4* or *IRF8* rescues the normal phenotype.^{39,40} Consistent with these roles in immune maturation and regulation, alterations in *IRF8*, as well as *IRF4*, have been implicated in B-cell malignancies, largely in adults, including follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.³³ This study adds to the complexity and importance of *IRF8* in B-cells and B-cell-related neoplasms.

Interactions between *IRF8* and *IRF4* have recently been described to have a co-regulatory role in Epstein–Barr virus infection.⁴¹ *IRF8* and *IRF4* directly interact with the N-terminal domain of the Epstein–Barr virus-encoded Epstein–Barr virus-associated nuclear antigen 3C forming a molecular complex, which stabilizes *IRF4* and leads to proteasome-dependent degradation of *IRF8*. Notably, an inverse relationship between *IRF8* expression and apoptosis resistance via Fas-mediated pathway has

been described to correlate with enhanced apoptosis resistance and metastatic potential *in vitro*.⁴² Given the association of EBV infection and altered *IRF8* activity with development and transformation of several lymphoproliferative disorders, it is intriguing to speculate that *IRF8* is the critical link in lymphomagenesis of many hematopoietic disorders.

We additionally identified a mutation in the transcription factor *PAX5/BSAP*, p.Gly183Ala. This amino acid, G183, has been identified as an important residue mutated in cases of B-lymphoblastic leukemia. On the basis of functional studies, mutations at G183 affect the transcriptional activity of *PAX5* and alter susceptibility to neoplasia.²¹ It is therefore not surprising that this mutation may additionally affect the progression and genesis of pediatric-type follicular lymphoma. This mutation was not present in the matched normal tissue, nor was it seen in the other cases of pediatric-type follicular lymphoma or pediatric nodal marginal zone lymphoma.

Similar to pediatric-type follicular lymphoma, the genetic underpinnings of pediatric nodal marginal zone lymphoma are not well understood. Rizzo *et al* reported 21% of cases of pediatric nodal marginal zone lymphomas contained genetic alterations detected by fluorescence *in situ* hybridization and reverse transcription PCR.¹¹ The leading abnormality was trisomy 18 (17%), which has been described in adult-type nodal marginal zone lymphoma.¹⁰ Our cohort showed no evidence of copy-number alterations to support trisomy. However, we identified a somatic variant in *AMOTL1* in a case of pediatric nodal marginal zone lymphoma, which has also been implicated in the pathogenesis of splenic marginal zone lymphoma.²⁹ This finding suggests that although pediatric nodal marginal zone lymphoma and adult-type nodal marginal zone lymphoma may share some common genetic abnormalities, our cohort is genetically distinct from adult-type nodal marginal zone lymphoma.

Unlike our pediatric-type follicular lymphoma cohort, a recurrent somatic mutation in our pediatric nodal marginal zone lymphoma cases was not identified by whole-exome sequencing. As the mutational burden was relatively lower in pediatric nodal marginal zone lymphoma than in pediatric-type follicular lymphoma (3.25 mutations per case versus 4.8 mutations per case), this might suggest that this disease may lack a common and specific driver. However, recent studies have suggested that somatic mutations in non-coding regions may harbor potential driver mutations and even synonymous alterations of protein coding genes may have functional roles in tumor development.^{43–45} Moreover, it has been recently shown that modification of the epigenetic landscape in adult-type follicular lymphoma through mutations in the methyltransferase *KMT2D* (*MLL2*) is prolymphomagenic; the possibility that non-coding DNA mutations or epigenetic

alterations may drive pediatric nodal marginal zone lymphoma warrants further study.⁴⁶

Overall, this is the first description of a broad somatic mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. The data support a different mechanism of development compared with the corresponding adult-type disease, as the typical mutational landscape found in adult-type nodal marginal zone lymphoma and adult-type follicular lymphoma was not present. Moreover, a single recurrent point mutation in *IRF8* was identified in a subset of pediatric-type follicular lymphoma cases, which was predicted to produce a deleterious effect. Given the functional role of IRF8 in B cells and transcription, it is intriguing to speculate that this mutation may serve as a driver-promoting disease development.

Acknowledgments

This work was supported through research funding to Ohgami RS through the Stanford Department of Pathology. We additionally thank Galli S, Lefterova M, Gojenola L, Chui W, West J and Chen R for their support.

Disclosure/conflict of interest

The authors declare no conflict of interest.

References

- O'Suoji C, Welch JJ, Perkins SL *et al*. Rare pediatric non-hodgkin lymphomas: A report from children's oncology group study ANHL 04B1. *Pediatr Blood Cancer* 2016;63:794–800.
- Quintanilla-Martinez L, Sander B, Chan JK *et al*. Indolent lymphomas in the pediatric population: Follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. *Virchows Arch* 2016;468:141–157.
- Swerdlow SH, Campo E, Pileri SA *et al*. The 2016 revision of the world health organization (WHO) classification of lymphoid neoplasms. *Blood* 2016;127:2375–2390.
- Lorsbach RB, Shay-Seymore D, Moore J *et al*. Clinico-pathologic analysis of follicular lymphoma occurring in children. *Blood* 2002;99:1959–1964.
- Ribeiro RC, Pui CH, Murphy SB *et al*. Childhood malignant non-hodgkin lymphomas of uncommon histology. *Leukemia* 1992;6:761–765.
- Martin-Guerrero I, Salaverria I, Burkhardt B *et al*. Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas. *Haematologica* 2013;98:1237–1241.
- Taddesse-Heath L, Pittaluga S, Sorbara L *et al*. Marginal zone B-cell lymphoma in children and young adults. *Am J Surg Pathol* 2003;27:522–531.
- Swerdlow SH, Campo E, Harris NL *et al*. (eds). *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, 4th edn. International Agency for Research on Cancer: Lyon, France, 2008.
- Harris NL, Swerdlow SH, Jaffe ES. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL *et al*. (eds). *World Health Organization Classification of Tumours*, 4th edn. International Agency for Research on Cancer: Lyon, France, 2008, pp 220.
- Dierlamm J, Pittaluga S, Wlodarska I *et al*. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. *Blood* 1996;87:299–307.
- Rizzo KA, Streubel B, Pittaluga S *et al*. Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR. *Mod Pathol* 2010;23:866–873.
- Karnik T, Ozawa MG, Lefterova M *et al*. The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma. *Hum Pathol* 2015;46:629–633.
- Palomero T, Couronne L, Khiabani H *et al*. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. *Nat Genet* 2014;46:166–170.
- Pasqualucci L, Khiabani H, Fangazio M *et al*. Genetics of follicular lymphoma transformation. *Cell Rep* 2014;6:130–140.
- Cibulskis K, Lawrence MS, Carter SL *et al*. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol* 2013;31:213–219.
- Ungewickell A, Bhaduri A, Rios E *et al*. Genomic analysis of mycosis fungoides and sezary syndrome identifies recurrent alterations in TNFR2. *Nat Genet* 2015;47:1056–1060.
- Ohgami RS, Ma L, Merker JD *et al*. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. *Mod Pathol* 2015;28:706–714.
- Biasini M, Bienert S, Waterhouse A *et al*. SWISS-MODEL: Modelling protein tertiary and quaternary structure using evolutionary information. *Nucleic Acids Res* 2014;42:W252–W258.
- Adzhubei IA, Schmidt S, Peshkin L *et al*. A method and server for predicting damaging missense mutations. *Nat Methods* 2010;7:248–249.
- Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 2009;4:1073–1081.
- Shah S, Schrader KA, Waanders E *et al*. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. *Nat Genet* 2013;45:1226–1231.
- Escalante CR, Brass AL, Pongubala JM *et al*. Crystal structure of PU.1/IRF-4/DNA ternary complex. *Mol Cell* 2002;10:1097–1105.
- Xie C, Tammi MT. CNV-seq, a new method to detect copy number variation using high-throughput sequencing. *BMC Bioinformatics* 2009;10:2105–10-80.
- Newman AM, Bratman SV, Stehr H *et al*. FACTERA: A practical method for the discovery of genomic rearrangements at breakpoint resolution. *Bioinformatics* 2014;30:3390–3393.
- Okosun J, Bodor C, Wang J *et al*. Integrated genomic analysis identifies recurrent mutations and evolution

- patterns driving the initiation and progression of follicular lymphoma. *Nat Genet* 2014;46:176–181.
- 26 Okosun J, Wolfson RL, Wang J *et al*. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. *Nat Genet* 2016;48:183–188.
 - 27 Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. *J Clin Invest* 2012;122:3424–3431.
 - 28 Loeffler M, Kreuz M, Haake A *et al*. HaematoSys-Project. Genomic and epigenomic co-evolution in follicular lymphomas. *Leukemia* 2015;29:456–463.
 - 29 Parry M, Rose-Zerilli MJ, Gibson J *et al*. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. *PLoS ONE* 2013;8:e83244.
 - 30 Clipson A, Wang M, de Leval L *et al*. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. *Leukemia* 2015;29:1177–1185.
 - 31 Martinez N, Almaraz C, Vaque JP *et al*. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. *Leukemia* 2014;28:1334–1340.
 - 32 Morin RD, Johnson NA, Severson TM *et al*. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet* 2010;42:181–185.
 - 33 Li H, Kaminski MS, Li Y *et al*. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. *Blood* 2014;123:1487–1498.
 - 34 Becker AM, Michael DG, Satpathy AT *et al*. IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors. *Blood* 2012;119:2003–2012.
 - 35 Ouyang X, Zhang R, Yang J *et al*. Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation. *Nat Commun* 2011;2:314.
 - 36 Xu H, Zhu J, Smith S *et al*. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. *Nat Immunol* 2012;13:642–650.
 - 37 Ma S, Pathak S, Trinh L *et al*. Interferon regulatory factors 4 and 8 induce the expression of ikaros and aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development. *Blood* 2008;111:1396–1403.
 - 38 Xu H, Chaudhri VK, Wu Z *et al*. Regulation of bifurcating B cell trajectories by mutual antagonism between transcription factors IRF4 and IRF8. *Nat Immunol* 2015;16:1274–1281.
 - 39 Ma S, Turetsky A, Trinh L *et al*. IFN regulatory factor 4 and 8 promote ig light chain kappa locus activation in pre-B cell development. *J Immunol* 2006;177:7898–7904.
 - 40 Ma S, Pathak S, Mandal M *et al*. Ikaros and aiolos inhibit pre-B-cell proliferation by directly suppressing c-myc expression. *Mol Cell Biol* 2010;30:4149–4158.
 - 41 Banerjee S, Lu J, Cai Q *et al*. The EBV latent antigen 3C inhibits apoptosis through targeted regulation of interferon regulatory factors 4 and 8. *PLoS Pathog* 2013;9:e1003314.
 - 42 Yang D, Thangaraju M, Greenelch K *et al*. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. *Cancer Res* 2007;67:3301–3309.
 - 43 Weinhold N, Jacobsen A, Schultz N *et al*. Genome-wide analysis of noncoding regulatory mutations in cancer. *Nat Genet* 2014;46:1160–1165.
 - 44 Fredriksson NJ, Ny L, Nilsson JA *et al*. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. *Nat Genet* 2014;46:1258–1263.
 - 45 Supek F, Minana B, Valcarcel J *et al*. Synonymous mutations frequently act as driver mutations in human cancers. *Cell* 2014;156:1324–1335.
 - 46 Zhang J, Dominguez-Sola D, Hussein S *et al*. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. *Nat Med* 2015;21:1190–1198.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>

© The Author(s) 2016

Supplementary Information accompanies the paper on *Modern Pathology* website (<http://www.nature.com/modpathol>)